A phase 2, multicenter study of FOLFIRINOX followed by ipilimumab in combination with allogeneic GM-CSF transfected pancreatic tumor vaccine in the treatment of metastatic pancreatic cancer.

Authors

Rina Khatri Patel

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Rina Khatri Patel , Andrew H. Ko , Beth Onners , Jennifer N. Uram , Rose Parkinson , Elizabeth Sugar , Eric Lutz , Lei Zheng , Daniel A. Laheru , Elizabeth M. Jaffee , Dung T. Le

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.

First Author: Shintaro Nakano

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2–positive metastatic pancreatic cancer (mPC).

First Author: Wungki Park

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Phase II study of GM-CSF secreting allogeneic pancreatic cancer vaccine (GVAX) with PD-1 blockade antibody and stereotactic body radiation therapy (SBRT) for locally advanced pancreas cancer (LAPC).

First Author: Valerie Lee

insert_chart_outlined

Poster

2015 Gastrointestinal Cancers Symposium

bookmark_border

Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer (mPC).

First Author: Daniel A. Goldstein